Detailed product reference
Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.
Product overview
Rozerem is an 8 mg melatonin-receptor agonist, distinct from benzodiazepines, Z-drugs and melatonin supplements.
Read source section ↗Mechanism of action
Acts at MT1/MT2 melatonin receptors rather than primarily at GABA-A receptors.
Read source section ↗Japanese indications & eligibility
Japanese use is insomnia-related sleep-onset difficulty. The prescription-only designation changed in September 2026; it remains a medical-use medicine.
Read source section ↗Administration & dose differences
Usually 8 mg before bedtime; avoid taking with/immediately after a meal and prepare to sleep.
Read source section ↗Adverse effects & key risks
Somnolence, dizziness and fatigue can impair next-day activities; persistent insomnia requires reassessment.
Read source section ↗Contraindications & special populations
Contraindicated with severe hepatic impairment, hypersensitivity or fluvoxamine use.
Read source section ↗Drug interactions
Fluvoxamine is contraindicated; review CYP modifiers, sedatives and alcohol.
Read source section ↗Assessment & monitoring
Track sleep onset, routine, daytime sedation and medication/alcohol use.
Read source section ↗Storage & handling
Store at room temperature in original packaging; the photo is the Japanese 8 mg blister.
Read source section ↗Sources & verification
Product checked ·
- PMDA electronic package insert ↗www.pmda.go.jp
Primary source for mechanism, indications, doses and risks; revision: 2026-09.
- Manufacturer information ↗www.takeda.com
Official product or related information; professional portals may require identity confirmation.
- Wikipedia: ingredient background ↗en.wikipedia.org
Background reference; Japanese approvals and administration are governed by PMDA sources.
